MeiraGTx up 5% after CEO sale filing
MeiraGTx shares rose 5.3% to $9.61 Wednesday after an SEC filing showed CEO Alexandria Forbes sold 62,000 shares under a pre-arranged plan, retaining 1.39 million. The company, now valued at $781 million, recently regained rights to bota-vec from Johnson & Johnson and received FDA Breakthrough Therapy Designation for AAV2-hAQP1. MeiraGTx reported no product revenue and a $46.3 million quarterly net loss.